10-K: Baxter International Inc. Reports Fiscal Year 2024 Results, Completes Kidney Care Business Sale

Baxter International Inc.'s 2024 10-K filing reveals a year of strategic shifts, including the sale of the Kidney Care business and a new operating model, alongside financial results impacted by Hurricane Helene and global economic conditions.

Summary

• Baxter International Inc. reported a 3% increase in global net sales, reaching $10.64 billion in 2024.
• International sales increased by 5% to $4.79 billion, while U.S. sales rose by 1% to $5.85 billion.
• The company experienced a net loss attributable to Baxter stockholders of $(649) million, or $(1.27) per diluted share, which included $2.13 billion in special items.
• Baxter completed the sale of its Kidney Care business to Carlyle Group for $3.80 billion in cash on January 31, 2025, receiving approximately $3.71 billion pre-tax.
• The company implemented a new operating model in the third quarter of 2023, reorganizing into three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
• Baxter repaid $3.65 billion of net debt during 2024 and through February 21, 2025, and is committed to achieving a net leverage target of approximately 3.0x by the end of 2025.
• Research and development expenditures totaled $590 million in 2024.
• Hurricane Helene had an estimated $110 million adverse impact on sales in 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making strategic moves to improve its financial position, the current financial results are mixed with a net loss and significant challenges.

Positives

• Global net sales increased by 3% in 2024.
• The sale of the Kidney Care business provides enhanced flexibility for capital allocation.
• Debt repayments are underway to achieve a net leverage target of approximately 3.0x by the end of 2025.
• The new operating model aims to simplify operations and improve efficiency.
• Advanced Surgery net sales increased 5% for the year ended December 31, 2024, as compared to the prior year period, driven by growth in hemostats and sealants and was primarily attributable to increased sales volume.
• Drug Compounding net sales increased 15% for the year ended December 31, 2024, as compared to the prior year period, driven by increased demand for our international pharmacy compounding offerings, due in part, to customer capacity constraints that resulted in increased outsourcing of compounding activities.

Negatives

• The company experienced a net loss attributable to Baxter stockholders of $(649) million in 2024.
• Hurricane Helene had a significant adverse impact on sales and operations.
• The Healthcare Systems & Technologies segment saw a 2% decrease in net sales.
• A $425 million goodwill impairment was recorded related to the Front Line Care reporting unit.
• The company reduced its quarterly dividend in November 2024.

Risks

• Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect operations.
• Failure to successfully integrate Hillrom or achieve expected operating efficiencies could impact financial performance.
• Competition and healthcare cost containment efforts may exert pressure on product pricing.
• Inability to attract, develop, retain, and engage key employees, including a permanent CEO, could harm the business.
• Quality management or product quality issues could lead to recalls and loss of customer confidence.
• Cybersecurity breaches and data leakage could have a material adverse effect on the business.
• Climate change and related regulations could adversely affect operations and financial results.
• The company is exposed to risks associated with doing business globally, including currency fluctuations and political instability.

Future Outlook

Baxter expects to use substantially all of the remaining net after-tax proceeds from the sale of our Kidney Care business to continue to repay indebtedness through the second quarter of 2025 and is committed to retaining our investment grade rating, including taking actions toward achieving a net leverage target of approximately 3.0x by the end of 2025 through ongoing debt repayment and financing activities.

Management Comments

• Management believes that providing the separate impact of the special items on our results in accordance with U.S. GAAP may provide a more complete understanding of our operations and can facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.

Industry Context

The announcement reflects a trend in the healthcare industry towards portfolio optimization and strategic reviews to enhance stockholder value, as well as the ongoing challenges of global supply chain disruptions and inflationary pressures.

Comparison to Industry Standards

• The company's strategic actions, such as the sale of the Kidney Care business, are similar to moves by other large healthcare companies like Medtronic and Johnson & Johnson, who have also been divesting non-core assets to focus on higher-growth areas.
• The target net leverage ratio of 3.0x is a common goal for investment-grade companies in the medical device industry, aligning with peers like Becton Dickinson and Stryker.
• The impact of Hurricane Helene on Baxter's IV solutions production highlights the vulnerability of medical product companies to supply chain disruptions, a challenge faced by many in the industry, including Abbott and Cardinal Health.
• The company's R&D spending as a percentage of revenue is comparable to that of other large medical device companies, such as Siemens Healthineers and Philips, who invest heavily in innovation to maintain competitiveness.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in product liability, patent, commercial, employment, and other legal matters that arise in the normal course of our business.
• Since December 2023, 41 lawsuits (after giving effect to the amendment referenced below) have been filed against us in the Circuit Court of Cook County, Illinois by plaintiffs alleging injuries as a result of exposure to ethylene oxide used by several companies, including historic use by us for sterilization at our facility in Round Lake, Illinois.
• In October 2022, the DOJ issued a separate Civil Investigative Demand (CID) addressed to Hillrom, requesting documents and information related to compliance with the False Claims Act and the Anti-Kickback Statute.
• On December 28, 2021, Linet Americas, Inc. (Linet) filed a complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Northern District of Illinois, captioned Linet Americas, Inc. v. Hill-Rom Holdings, Inc.; Hill-Rom Company, Inc.; Hill-Rom Services, Inc.
• On June 20, 2024, Reading Hospital filed a putative class action complaint against Hill-Rom Holdings, Inc., Hill-Rom Company, Inc., and Hill-Rom Services, Inc. in the United States District Court for the Eastern District of Pennsylvania.

Stakeholder Impact

• Shareholders: Strategic actions aim to increase stockholder value, but short-term financial results may be volatile.
• Employees: Restructuring and cost reduction initiatives may lead to workforce changes.
• Customers: Efforts are made to minimize disruption to patient care during supply chain challenges.
• Suppliers: The company works closely with suppliers to ensure availability and continuity of supply.
• Creditors: Debt repayment is a priority to maintain an investment-grade rating.

Next Steps

• Continue debt repayment to reach net leverage target of 3.0x by the end of 2025.
• Undertake additional actions to ensure that our cost structure is appropriate to support our remaining businesses.
• Fully remediate the North Cove facility.

Key Dates